Note 15 - Segments (Tables)

3 Months Ended

Mar. 31, 2019

T hree Months Ended March 31, 2019	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	3,150		$	—		$	—		$	3,150
Sublease revenue		—			—			94,408			94,408
Grant and other revenue		35,991			2,483			—			38,474
Total revenue		39,141			2,483			94,408			136,032
Cost of revenue		6,126			—			—			6,126
Research and development expenses		740,583			—			—			740,583
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			11,714			1,774,431			1,786,145
Depreciation and amortization (2)		—			—			36,779			36,779
Loss from operations (3)		(707,568	)		(9,231	)		(1,716,802	)		(2,433,601	)
Other income (4)		—			—			8,713			8,713
Provision for income taxes		(256	)		(3	)		(617	)		(876	)
Net loss from continuing operations		(707,824	)		(9,234	)		(1,708,706	)		(2,425,764	)
Loss from discontinued operations, net of tax		(3,297	)		—			—			(3,297	)
Net loss		(711,121	)		(9,234	)		(1,708,706	)		(2,429,061	)
Total assets, net of depreciation and amortization:
United States	$	55,213		$	2,411		$	4,891,112		$	4,948,736
International		10,422			—			602			11,024
Capital expenditures		—			—			—			—

T hree Months Ended March 31, 2018	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	795		$	—		$	—		$	795
Grant and other revenue		232,436			43,214			—			275,650
Total revenue		233,231			43,214			—			276,445
Cost of revenue		318			—			—			318
Research and development expenses		785,011			213,945			—			998,956
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			8,607			1,729,778			1,738,385
Depreciation and amortization (2)		—			—			37,987			37,987
Loss from operations (3)		(552,098	)		(179,338	)		(1,767,765	)		(2,499,201	)
Other expense (4)		—			—			(4,238,761	)		(4,238,761	)
Net loss		(552,098	)		(179,338	)		(6,006,526	)		(6,737,962	)
Total assets, net of depreciation and amortization:
United States	$	13,077,979		$	27,228		$	5,189,637		$	18,294,844
International		26,055			—			1,328			27,383
Capital expenditures		—			—			—			—